DLL3在小细胞肺癌中的表达及其在靶向治疗中的应用

国际肿瘤学杂志 Pub Date : 2019-06-18 DOI:10.3760/CMA.J.ISSN.1673-422X.2019.06.011

H. Zuo, Na Li, Luojun Chen, Hua-li Liu

{"title":"DLL3在小细胞肺癌中的表达及其在靶向治疗中的应用","authors":"H. Zuo, Na Li, Luojun Chen, Hua-li Liu","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.011","DOIUrl":null,"url":null,"abstract":"Small cell lung cancer (SCLC) has a poor biological behavior, high probability of recurrence and metastasis, and limited treatment. The Notch signaling pathway is an evolutionarily conserved pathway that regulates the growth of many cell types through local cell-cell interactions. It controls the differentiation, proliferation and survival of cells. As a ligand for the Notch pathway, delta-like protein 3 (DLL3) is highly expressed on the membrane of SCLC cells. DLL3 plays an important role in cancer initiation and epithelial mesenchymal transition, invasion and metastasis of SCLC. Rovalpituzumab tesirine is a conjugate of directed against DLL3, which shows great potential for SCLC therapy. \n \n \nKey words: \nSmall cell lung carcinoma; Receptors, Notch; Delta-like protein 3","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"68 1","pages":"366-369"},"PeriodicalIF":0.0000,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expression of DLL3 in small cell lung cancer and its application in targeted therapy\",\"authors\":\"H. Zuo, Na Li, Luojun Chen, Hua-li Liu\",\"doi\":\"10.3760/CMA.J.ISSN.1673-422X.2019.06.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Small cell lung cancer (SCLC) has a poor biological behavior, high probability of recurrence and metastasis, and limited treatment. The Notch signaling pathway is an evolutionarily conserved pathway that regulates the growth of many cell types through local cell-cell interactions. It controls the differentiation, proliferation and survival of cells. As a ligand for the Notch pathway, delta-like protein 3 (DLL3) is highly expressed on the membrane of SCLC cells. DLL3 plays an important role in cancer initiation and epithelial mesenchymal transition, invasion and metastasis of SCLC. Rovalpituzumab tesirine is a conjugate of directed against DLL3, which shows great potential for SCLC therapy. \\n \\n \\nKey words: \\nSmall cell lung carcinoma; Receptors, Notch; Delta-like protein 3\",\"PeriodicalId\":16120,\"journal\":{\"name\":\"国际肿瘤学杂志\",\"volume\":\"68 1\",\"pages\":\"366-369\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际肿瘤学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

小细胞肺癌(Small cell lung cancer, SCLC)生物学行为差，复发转移概率高，治疗受限。Notch信号通路是一种进化保守的通路，通过局部细胞间相互作用调节多种细胞类型的生长。它控制着细胞的分化、增殖和存活。delta-like protein 3 (DLL3)作为Notch通路的配体，在SCLC细胞膜上高表达。DLL3在SCLC的癌变起始和上皮间质转移、侵袭转移中起重要作用。Rovalpituzumab tesirine是一种靶向DLL3的偶联物，在SCLC治疗中显示出巨大的潜力。关键词:小细胞肺癌;受体,切口;δ样蛋白

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Expression of DLL3 in small cell lung cancer and its application in targeted therapy

Small cell lung cancer (SCLC) has a poor biological behavior, high probability of recurrence and metastasis, and limited treatment. The Notch signaling pathway is an evolutionarily conserved pathway that regulates the growth of many cell types through local cell-cell interactions. It controls the differentiation, proliferation and survival of cells. As a ligand for the Notch pathway, delta-like protein 3 (DLL3) is highly expressed on the membrane of SCLC cells. DLL3 plays an important role in cancer initiation and epithelial mesenchymal transition, invasion and metastasis of SCLC. Rovalpituzumab tesirine is a conjugate of directed against DLL3, which shows great potential for SCLC therapy. Key words: Small cell lung carcinoma; Receptors, Notch; Delta-like protein 3

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

国际肿瘤学杂志

自引率

0.00%

发文量

12123

期刊介绍：